We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Protagen AG and MicroDiscovery GmbH Cooperate in Biomarker Development


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Protagen AG and MicroDiscovery GmbH Cooperate in Biomarker Development"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 
Dortmund based Protagen AG, a specialist in in-vitro diagnostics and GMP-conform protein analytics and MicroDiscovery GmbH, a bioinformatics company based in Berlin, have started a cooperation to identify and validate biomarkers for medically relevant diseases.

"Our proprietary technology platform UNIarray® and MicroDiscovery's certified software solutions for the analysis of complex marker panels complement each other perfectly," states Dr. Peter Schulz-Knappe, CSO and Executive Vice President Diagnostics of Protagen AG and adds: "The cooperation strengthens our position in biomarker development and supports the efficient development of marketable products."

Dr. Arif Malik, CEO of MicroDiscovery GmbH, confirms: "Our experience in analyzing clinical studies for multiplex assays and array data perfectly fits with Protagen's established screening platform. This illustrates the value of MicroDiscovery's bioinformatics methods and software solutions for the development of new diagnostics."
Advertisement